This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug ...

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of last year’s protection. The coronavirus and influenza are escape artists that ...

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...

Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.